Alternate-day dosing of atorvastatin: Effects in treating type 2 diabetic patients with dyslipidaemia

Acta Diabetologica

Volumn 43, Issue 3, 2006, Pages 75-78

  Ferrer Garcia J C ^a   Perez Silvestre J ^b   Martinez Mir I ^a   Herrera Ballester, A ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Atorvastatin; Cholesterol; Dyslipidaemia; Low density lipoprotein; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ATORVASTATIN; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; SPAIN;

EID: 33845315553     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-006-0216-4     Document Type: Article

References (14)

1. Turner RC, Millns H, Neil HA, Stratton IM, Manlay SE, Mathews DR, Holman RR (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus (UKPDS 23). BMJ 316:823-828
2. American Diabetes Association (2004) Clinical Practice Recommendation. Diabetes Care 27:S1-S150
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Panel Treatment III) final report. (2002) Circulation 106:3143-3321
4. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM (1995) Reduction of LDL-cholesterol by 25 to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15:678-682
5. Lea AP, McTavisch D (1997) Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 53:828-847
6. Friedwald WT, Levy RI, Frederickson DS (1972) Estimation of concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem 18:499-502
7. Matalka MS, Ravnan MC, Deedwania MD (2002) Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 144:674-677
8. Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M (2003) Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther 8:123-126
9. Copher HR, Stewart RD (2002) Daily dosing versus alternate-day dosing of simvastatin in patients with hypercholesterolemia. Pharmacotherapy 22:110-116
10. Dennis VC, Britton ML, Sirmans SM, Letassy NA, Freeman DA (1997) The use of alternate-day lovastatin in hypercholesterolemic men. Ann Pharmacother 31:708-712
11. Piamsomboon C, Laothavorn P, Saguanwong S, Chataong B, Nasaw C, Tanprasert P, Pongsiri K (2002) Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia. J Med Assoc Thai 85:297-300
12. Jones PH, McKenney JM, Karalis DG, Downey J (2005) Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J 149:e1-e8
13. American Diabetes Association (2003) Management of dyslipidemia in adults with diabetes. Diabetes Care 4:325-328
14. Iliff RD (2002) Weekly versus daily dosing of atorvastatin. J Fam Pract 51:365-366